Group Company Held Symposium for Scientific and Technical Personnel and Young Employees
Release time:
2021-02-10
zero distance listening face-to-face communication
group company held a symposium for scientific and technological personnel and young employees
on January 29, the annual symposium for scientific and technological personnel and young employees was held at the group headquarters. The leaders of the group company and the employee representatives of each unit communicate face-to-face, and the employee representatives express their opinions, speak freely, and share their experience and work experience in the post. At the scientific and technological personnel forum on the morning of
, the representatives mainly put forward their own opinions and suggestions from the aspects of technical transformation, work docking, process optimization, organization and management, etc. Yu Jianhong, general manager of
Group Company, said in the exchange that scientific and technological strength is the core competitiveness of enterprises, and scientific and technological personnel represent the hope of the future. He put forward suggestions to scientific and technological personnel: do their own work conscientiously; have the courage to take responsibility, adhere to the original intention and dare to speak the truth; continue to learn, be good at learning, actively improve their own quality, and maintain their own advantages; have more feelings and more persistence, resist many temptations in modern society, and do business in a down-to-earth manner; always maintain a positive and optimistic attitude. Jiang Xiaomeng, chairman of
group company, put forward two hopes for the transformation and upgrading of science and technology and scientific and technological innovation of enterprises: first, he hopes that the management of enterprises will introduce incentive policies and support policies to help scientific and technological personnel innovate and empower them, and give them the opportunity to learn advanced technology and advanced enterprises. Second, it is hoped that young scientific and technological personnel will seize the opportunity and organically combine the advantages of knowledge and ability with the opportunity. At the youth employee forum held in the afternoon of
, young employee representatives actively expressed their views. They paid more attention to living treatment, spare time activities, learning and training, and equipment update and maintenance.
Chairman Jiang Xiaomeng reviewed the anti-epidemic achievements and achievements of Jianfeng Group over the past year, and introduced the operation of each subsidiary company to the delegates. He said that the group company holds a symposium every year. Young people are the future of the peak, and caring for employees is part of the peak culture. The company is currently operating in good condition, but we need to see the crisis and risks of future market changes. Enterprises are the main body of self-financing and self-responsibility. The improvement of employees' welfare benefits requires enterprises to maintain competitiveness and profitability. The competitiveness and profitability of enterprises need to be jointly maintained by employees, and they should not be complacent and overjoyed. All employees should work hard to learn and grow into irreplaceable talents, improve and improve the weak links of each enterprise, do fine and excellent, and make common progress with the enterprise.
The opinions and suggestions of the staff representatives on the questions raised at the symposium were answered on the spot during the exchange, and the remaining suggestions, opinions, and suggestions were summarized and classified by a special person after the meeting, and implemented one by one after research and judgment. Reasonable and immediately instruct the person in charge of each unit to improve and solve, and the immature or individual problems will also be explained.
Guizhou Jianfeng, Daye Jianfeng, Yunnan Jianfeng and other overseas enterprises also participated simultaneously through the remote conference system. (Reporter Chen Shengmu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page